

# Global Targeted Protein Degradation (TPD) Therapy Drugs Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

<https://marketpublishers.com/r/T0F3BCF73F0EEN.html>

Date: January 2026

Pages: 170

Price: US\$ 3,480.00 (Single User License)

ID: T0F3BCF73F0EEN

## Abstracts

According to our (Global Info Research) latest study, the global Targeted Protein Degradation (TPD) Therapy Drugs market size was valued at US\$ 20827 million in 2025 and is forecast to a readjusted size of US\$ 40071 million by 2032 with a CAGR of 10.3% during review period.

In 2025, global Targeted protein degradation (TPD) Therapy Drugs reached approximately 1338 K Units, with an average global market price of around 121.33 USD per Unit.

Targeted Protein Degradation (TPD) therapy drugs are a class of innovative medicines that treat disease by selectively eliminating specific proteins inside cells, rather than merely inhibiting their activity. These therapies work by harnessing the cell's natural protein disposal systems, most commonly the ubiquitin–proteasome pathway or, in some cases, lysosomal degradation pathways, to remove disease-causing or disease-driving proteins.

Targeted protein degradation (TPD) Therapy Drugs are an emerging class of small-molecule medicines designed to treat disease by selectively removing, rather than merely inhibiting, specific proteins through the cell's own ubiquitin–proteasome degradation system. This “event-driven” mechanism addresses several persistent pain points in drug development: it can overcome situations where conventional inhibitors lose effectiveness due to resistance mutations, it can achieve deeper and more sustained pathway control by eliminating the target protein altogether, and it opens new possibilities for proteins that are difficult to modulate with classic active-site binding strategies. Industry momentum is being fueled by rapid advances in target biology and

structural design, growing confidence in the translational value of targeted protein degradation, and strong demand in areas such as oncology and immune-mediated diseases where durable responses and differentiation matter most. Looking ahead, market potential is supported by an expanding pipeline of degrader programs, improving chemistry and drug-like properties that enable more practical dosing and broader tissue reach, and the likelihood that successful Targeted protein degradation (TPD) Therapy Drugs will complement—rather than simply replace—existing targeted therapies, creating a meaningful new layer of precision medicine built around controlling protein levels instead of just protein activity.

The upstream raw materials for Targeted Protein Degradation (TPD) Therapy Drugs mainly include target protein (POI) ligands, E3 ligase ligands, excipients, etc. Typical suppliers include Bio-Techne, Merck, Sigma-Aldrich, Enamine, etc. The downstream applications are mainly in the treatment of cancer, immune diseases, etc.

The production capacity of Targeted protein degradation (TPD) Therapy Drugs varies significantly depending on the technology route, production stage, and commercialization progress. The gross profit margin of Targeted protein degradation (TPD) Therapy Drugs is usually between 70-80%.

This report is a detailed and comprehensive analysis for global Targeted Protein Degradation (TPD) Therapy Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

### **Key Features:**

Global Targeted Protein Degradation (TPD) Therapy Drugs market size and forecasts, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2021-2032

Global Targeted Protein Degradation (TPD) Therapy Drugs market size and forecasts by region and country, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2021-2032

Global Targeted Protein Degradation (TPD) Therapy Drugs market size and forecasts, by Type and by Application, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2021-2032

Global Targeted Protein Degradation (TPD) Therapy Drugs market shares of main players, shipments in revenue (\$ Million), sales quantity (K Units), and ASP (US\$/Unit), 2021-2026

### **The Primary Objectives in This Report Are:**

- To determine the size of the total market opportunity of global and key countries
- To assess the growth potential for Targeted Protein Degradation (TPD) Therapy Drugs
- To forecast future growth in each product and end-use market
- To assess competitive factors affecting the marketplace

This report profiles key players in the global Targeted Protein Degradation (TPD) Therapy Drugs market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include BMS, Arvinas, Kymera, Nurix, C4 Therapeutics, Cullgen, Kintor Pharma, Prelude Therapeutics, AbbVie, Accutar, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

### **Market Segmentation**

Targeted Protein Degradation (TPD) Therapy Drugs market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

#### **Market segment by Type**

PROTAC

Molecular Glues

Others

#### Market segment by Target Protein

Degradation of Transcription Factors Type

Degradation of Scaffold Proteins Type

Others

#### Market segment by Administration Route

Oral Drugs

Injectable Drugs

Others

#### **Market segment by Application**

Cancer

Immune Diseases

Others

#### Major players covered

BMS

Arvinas

Kymera

Nurix

C4 Therapeutics

Cullgen

Kintor Pharma

Prelude Therapeutics

AbbVie

Accutar

AnHorn Medicines

Astellas

Auron Therapeutics

Axter Therapeutics

Biotheryx

Dialectic Therapeutics

Hinova

Hinova Pharmaceuticals

Haisco

Leadingtac

Mitsubishi Tanabe Pharma America

NiKang Therapeutics

Ubix Therapeutics

Foghorn Therapeutics

Beigene, Ltd.

Jiangsu Hengrui Medicine

Qilu Pharmaceutical

Simcere Pharma

Chia Tai Tianqing Pharmaceutical

Market segment by region, regional analysis covers  
North America (United States, Canada, and Mexico)  
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)  
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)  
South America (Brazil, Argentina, Colombia, and Rest of South America)  
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

**The content of the study subjects, includes a total of 15 chapters:**

Chapter 1, to describe Targeted Protein Degradation (TPD) Therapy Drugs product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Targeted Protein Degradation (TPD) Therapy Drugs, with price, sales quantity, revenue, and global market share of Targeted Protein Degradation (TPD) Therapy Drugs from 2021 to 2026.

Chapter 3, the Targeted Protein Degradation (TPD) Therapy Drugs competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Targeted Protein Degradation (TPD) Therapy Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.

Chapter 5 and 6, to segment the sales by Type and by Application, with sales market

share and growth rate by Type, by Application, from 2021 to 2032.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026. and Targeted Protein Degradation (TPD) Therapy Drugs market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.

Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Targeted Protein Degradation (TPD) Therapy Drugs.

Chapter 14 and 15, to describe Targeted Protein Degradation (TPD) Therapy Drugs sales channel, distributors, customers, research findings and conclusion.

## Contents

### 1 MARKET OVERVIEW

1.1 Product Overview and Scope

1.2 Market Estimation Caveats and Base Year

1.3 Market Analysis by Type

1.3.1 Overview: Global Targeted Protein Degradation (TPD) Therapy Drugs  
Consumption Value by Type: 2021 Versus 2025 Versus 2032

1.3.2 PROTAC

1.3.3 Molecular Glues

1.3.4 Others

1.4 Market Analysis by Target Protein

1.4.1 Overview: Global Targeted Protein Degradation (TPD) Therapy Drugs  
Consumption Value by Target Protein: 2021 Versus 2025 Versus 2032

1.4.2 Degradation of Transcription Factors Type

1.4.3 Degradation of Scaffold Proteins Type

1.4.4 Others

1.5 Market Analysis by Administration Route

1.5.1 Overview: Global Targeted Protein Degradation (TPD) Therapy Drugs  
Consumption Value by Administration Route: 2021 Versus 2025 Versus 2032

1.5.2 Oral Drugs

1.5.3 Injectable Drugs

1.5.4 Others

1.6 Market Analysis by Application

1.6.1 Overview: Global Targeted Protein Degradation (TPD) Therapy Drugs  
Consumption Value by Application: 2021 Versus 2025 Versus 2032

1.6.2 Cancer

1.6.3 Immune Diseases

1.6.4 Others

1.7 Global Targeted Protein Degradation (TPD) Therapy Drugs Market Size & Forecast

1.7.1 Global Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value  
(2021 & 2025 & 2032)

1.7.2 Global Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity  
(2021-2032)

1.7.3 Global Targeted Protein Degradation (TPD) Therapy Drugs Average Price  
(2021-2032)

### 2 MANUFACTURERS PROFILES

## 2.1 BMS

### 2.1.1 BMS Details

### 2.1.2 BMS Major Business

### 2.1.3 BMS Targeted Protein Degradation (TPD) Therapy Drugs Product and Services

### 2.1.4 BMS Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

### 2.1.5 BMS Recent Developments/Updates

## 2.2 Arvinas

### 2.2.1 Arvinas Details

### 2.2.2 Arvinas Major Business

### 2.2.3 Arvinas Targeted Protein Degradation (TPD) Therapy Drugs Product and Services

### 2.2.4 Arvinas Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

### 2.2.5 Arvinas Recent Developments/Updates

## 2.3 Kymera

### 2.3.1 Kymera Details

### 2.3.2 Kymera Major Business

### 2.3.3 Kymera Targeted Protein Degradation (TPD) Therapy Drugs Product and Services

### 2.3.4 Kymera Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

### 2.3.5 Kymera Recent Developments/Updates

## 2.4 Nurix

### 2.4.1 Nurix Details

### 2.4.2 Nurix Major Business

### 2.4.3 Nurix Targeted Protein Degradation (TPD) Therapy Drugs Product and Services

### 2.4.4 Nurix Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

### 2.4.5 Nurix Recent Developments/Updates

## 2.5 C4 Therapeutics

### 2.5.1 C4 Therapeutics Details

### 2.5.2 C4 Therapeutics Major Business

### 2.5.3 C4 Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Product and Services

### 2.5.4 C4 Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

### 2.5.5 C4 Therapeutics Recent Developments/Updates

## 2.6 Cullgen

### 2.6.1 Cullgen Details

### 2.6.2 Cullgen Major Business

### 2.6.3 Cullgen Targeted Protein Degradation (TPD) Therapy Drugs Product and Services

### 2.6.4 Cullgen Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

### 2.6.5 Cullgen Recent Developments/Updates

## 2.7 Kintor Pharma

### 2.7.1 Kintor Pharma Details

### 2.7.2 Kintor Pharma Major Business

### 2.7.3 Kintor Pharma Targeted Protein Degradation (TPD) Therapy Drugs Product and Services

### 2.7.4 Kintor Pharma Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

### 2.7.5 Kintor Pharma Recent Developments/Updates

## 2.8 Prelude Therapeutics

### 2.8.1 Prelude Therapeutics Details

### 2.8.2 Prelude Therapeutics Major Business

### 2.8.3 Prelude Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Product and Services

### 2.8.4 Prelude Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

### 2.8.5 Prelude Therapeutics Recent Developments/Updates

## 2.9 AbbVie

### 2.9.1 AbbVie Details

### 2.9.2 AbbVie Major Business

### 2.9.3 AbbVie Targeted Protein Degradation (TPD) Therapy Drugs Product and Services

### 2.9.4 AbbVie Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

### 2.9.5 AbbVie Recent Developments/Updates

## 2.10 Accutar

### 2.10.1 Accutar Details

### 2.10.2 Accutar Major Business

### 2.10.3 Accutar Targeted Protein Degradation (TPD) Therapy Drugs Product and Services

### 2.10.4 Accutar Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

- 2.10.5 Accutar Recent Developments/Updates
- 2.11 AnHorn Medicines
  - 2.11.1 AnHorn Medicines Details
  - 2.11.2 AnHorn Medicines Major Business
  - 2.11.3 AnHorn Medicines Targeted Protein Degradation (TPD) Therapy Drugs Product and Services
  - 2.11.4 AnHorn Medicines Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  - 2.11.5 AnHorn Medicines Recent Developments/Updates
- 2.12 Astellas
  - 2.12.1 Astellas Details
  - 2.12.2 Astellas Major Business
  - 2.12.3 Astellas Targeted Protein Degradation (TPD) Therapy Drugs Product and Services
  - 2.12.4 Astellas Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  - 2.12.5 Astellas Recent Developments/Updates
- 2.13 Auron Therapeutics
  - 2.13.1 Auron Therapeutics Details
  - 2.13.2 Auron Therapeutics Major Business
  - 2.13.3 Auron Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Product and Services
  - 2.13.4 Auron Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  - 2.13.5 Auron Therapeutics Recent Developments/Updates
- 2.14 Axter Therapeutics
  - 2.14.1 Axter Therapeutics Details
  - 2.14.2 Axter Therapeutics Major Business
  - 2.14.3 Axter Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Product and Services
  - 2.14.4 Axter Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  - 2.14.5 Axter Therapeutics Recent Developments/Updates
- 2.15 Biotheryx
  - 2.15.1 Biotheryx Details
  - 2.15.2 Biotheryx Major Business
  - 2.15.3 Biotheryx Targeted Protein Degradation (TPD) Therapy Drugs Product and Services
  - 2.15.4 Biotheryx Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity,

Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.15.5 Biotheryx Recent Developments/Updates

2.16 Dialectic Therapeutics

2.16.1 Dialectic Therapeutics Details

2.16.2 Dialectic Therapeutics Major Business

2.16.3 Dialectic Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Product and Services

2.16.4 Dialectic Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.16.5 Dialectic Therapeutics Recent Developments/Updates

2.17 Hinoa

2.17.1 Hinoa Details

2.17.2 Hinoa Major Business

2.17.3 Hinoa Targeted Protein Degradation (TPD) Therapy Drugs Product and Services

2.17.4 Hinoa Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.17.5 Hinoa Recent Developments/Updates

2.18 Hinoa Pharmaceuticals

2.18.1 Hinoa Pharmaceuticals Details

2.18.2 Hinoa Pharmaceuticals Major Business

2.18.3 Hinoa Pharmaceuticals Targeted Protein Degradation (TPD) Therapy Drugs Product and Services

2.18.4 Hinoa Pharmaceuticals Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.18.5 Hinoa Pharmaceuticals Recent Developments/Updates

2.19 Haisco

2.19.1 Haisco Details

2.19.2 Haisco Major Business

2.19.3 Haisco Targeted Protein Degradation (TPD) Therapy Drugs Product and Services

2.19.4 Haisco Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.19.5 Haisco Recent Developments/Updates

2.20 Leadingtac

2.20.1 Leadingtac Details

2.20.2 Leadingtac Major Business

2.20.3 Leadingtac Targeted Protein Degradation (TPD) Therapy Drugs Product and Services

2.20.4 Leadingtac Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.20.5 Leadingtac Recent Developments/Updates

2.21 Mitsubishi Tanabe Pharma America

2.21.1 Mitsubishi Tanabe Pharma America Details

2.21.2 Mitsubishi Tanabe Pharma America Major Business

2.21.3 Mitsubishi Tanabe Pharma America Targeted Protein Degradation (TPD) Therapy Drugs Product and Services

2.21.4 Mitsubishi Tanabe Pharma America Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.21.5 Mitsubishi Tanabe Pharma America Recent Developments/Updates

2.22 NiKang Therapeutics

2.22.1 NiKang Therapeutics Details

2.22.2 NiKang Therapeutics Major Business

2.22.3 NiKang Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Product and Services

2.22.4 NiKang Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.22.5 NiKang Therapeutics Recent Developments/Updates

2.23 Ubix Therapeutics

2.23.1 Ubix Therapeutics Details

2.23.2 Ubix Therapeutics Major Business

2.23.3 Ubix Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Product and Services

2.23.4 Ubix Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.23.5 Ubix Therapeutics Recent Developments/Updates

2.24 Foghorn Therapeutics

2.24.1 Foghorn Therapeutics Details

2.24.2 Foghorn Therapeutics Major Business

2.24.3 Foghorn Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Product and Services

2.24.4 Foghorn Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.24.5 Foghorn Therapeutics Recent Developments/Updates

2.25 Beigene, Ltd.

2.25.1 Beigene, Ltd. Details

2.25.2 Beigene, Ltd. Major Business

2.25.3 Beigene, Ltd. Targeted Protein Degradation (TPD) Therapy Drugs Product and Services

2.25.4 Beigene, Ltd. Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.25.5 Beigene, Ltd. Recent Developments/Updates

2.26 Jiangsu Hengrui Medicine

2.26.1 Jiangsu Hengrui Medicine Details

2.26.2 Jiangsu Hengrui Medicine Major Business

2.26.3 Jiangsu Hengrui Medicine Targeted Protein Degradation (TPD) Therapy Drugs Product and Services

2.26.4 Jiangsu Hengrui Medicine Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.26.5 Jiangsu Hengrui Medicine Recent Developments/Updates

2.27 Qilu Pharmaceutical

2.27.1 Qilu Pharmaceutical Details

2.27.2 Qilu Pharmaceutical Major Business

2.27.3 Qilu Pharmaceutical Targeted Protein Degradation (TPD) Therapy Drugs Product and Services

2.27.4 Qilu Pharmaceutical Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.27.5 Qilu Pharmaceutical Recent Developments/Updates

2.28 Simcere Pharma

2.28.1 Simcere Pharma Details

2.28.2 Simcere Pharma Major Business

2.28.3 Simcere Pharma Targeted Protein Degradation (TPD) Therapy Drugs Product and Services

2.28.4 Simcere Pharma Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.28.5 Simcere Pharma Recent Developments/Updates

2.29 Chia Tai Tianqing Pharmaceutical

2.29.1 Chia Tai Tianqing Pharmaceutical Details

2.29.2 Chia Tai Tianqing Pharmaceutical Major Business

2.29.3 Chia Tai Tianqing Pharmaceutical Targeted Protein Degradation (TPD) Therapy Drugs Product and Services

2.29.4 Chia Tai Tianqing Pharmaceutical Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.29.5 Chia Tai Tianqing Pharmaceutical Recent Developments/Updates

### **3 COMPETITIVE ENVIRONMENT: TARGETED PROTEIN DEGRADATION (TPD) THERAPY DRUGS BY MANUFACTURER**

3.1 Global Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Manufacturer (2021-2026)

3.2 Global Targeted Protein Degradation (TPD) Therapy Drugs Revenue by Manufacturer (2021-2026)

3.3 Global Targeted Protein Degradation (TPD) Therapy Drugs Average Price by Manufacturer (2021-2026)

3.4 Market Share Analysis (2025)

3.4.1 Producer Shipments of Targeted Protein Degradation (TPD) Therapy Drugs by Manufacturer Revenue (\$MM) and Market Share (%): 2025

3.4.2 Top 3 Targeted Protein Degradation (TPD) Therapy Drugs Manufacturer Market Share in 2025

3.4.3 Top 6 Targeted Protein Degradation (TPD) Therapy Drugs Manufacturer Market Share in 2025

3.5 Targeted Protein Degradation (TPD) Therapy Drugs Market: Overall Company Footprint Analysis

3.5.1 Targeted Protein Degradation (TPD) Therapy Drugs Market: Region Footprint

3.5.2 Targeted Protein Degradation (TPD) Therapy Drugs Market: Company Product Type Footprint

3.5.3 Targeted Protein Degradation (TPD) Therapy Drugs Market: Company Product Application Footprint

3.6 New Market Entrants and Barriers to Market Entry

3.7 Mergers, Acquisition, Agreements, and Collaborations

### **4 CONSUMPTION ANALYSIS BY REGION**

4.1 Global Targeted Protein Degradation (TPD) Therapy Drugs Market Size by Region

4.1.1 Global Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Region (2021-2032)

4.1.2 Global Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value by Region (2021-2032)

4.1.3 Global Targeted Protein Degradation (TPD) Therapy Drugs Average Price by Region (2021-2032)

4.2 North America Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value (2021-2032)

4.3 Europe Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value (2021-2032)

4.4 Asia-Pacific Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value (2021-2032)

4.5 South America Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value (2021-2032)

4.6 Middle East & Africa Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value (2021-2032)

## **5 MARKET SEGMENT BY TYPE**

5.1 Global Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Type (2021-2032)

5.2 Global Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value by Type (2021-2032)

5.3 Global Targeted Protein Degradation (TPD) Therapy Drugs Average Price by Type (2021-2032)

## **6 MARKET SEGMENT BY APPLICATION**

6.1 Global Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Application (2021-2032)

6.2 Global Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value by Application (2021-2032)

6.3 Global Targeted Protein Degradation (TPD) Therapy Drugs Average Price by Application (2021-2032)

## **7 NORTH AMERICA**

7.1 North America Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Type (2021-2032)

7.2 North America Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Application (2021-2032)

7.3 North America Targeted Protein Degradation (TPD) Therapy Drugs Market Size by Country

7.3.1 North America Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Country (2021-2032)

7.3.2 North America Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value by Country (2021-2032)

7.3.3 United States Market Size and Forecast (2021-2032)

7.3.4 Canada Market Size and Forecast (2021-2032)

### 7.3.5 Mexico Market Size and Forecast (2021-2032)

## 8 EUROPE

8.1 Europe Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Type (2021-2032)

8.2 Europe Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Application (2021-2032)

8.3 Europe Targeted Protein Degradation (TPD) Therapy Drugs Market Size by Country

8.3.1 Europe Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Country (2021-2032)

8.3.2 Europe Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value by Country (2021-2032)

8.3.3 Germany Market Size and Forecast (2021-2032)

8.3.4 France Market Size and Forecast (2021-2032)

8.3.5 United Kingdom Market Size and Forecast (2021-2032)

8.3.6 Russia Market Size and Forecast (2021-2032)

8.3.7 Italy Market Size and Forecast (2021-2032)

## 9 ASIA-PACIFIC

9.1 Asia-Pacific Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Type (2021-2032)

9.2 Asia-Pacific Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Application (2021-2032)

9.3 Asia-Pacific Targeted Protein Degradation (TPD) Therapy Drugs Market Size by Region

9.3.1 Asia-Pacific Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Region (2021-2032)

9.3.2 Asia-Pacific Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value by Region (2021-2032)

9.3.3 China Market Size and Forecast (2021-2032)

9.3.4 Japan Market Size and Forecast (2021-2032)

9.3.5 South Korea Market Size and Forecast (2021-2032)

9.3.6 India Market Size and Forecast (2021-2032)

9.3.7 Southeast Asia Market Size and Forecast (2021-2032)

9.3.8 Australia Market Size and Forecast (2021-2032)

## 10 SOUTH AMERICA

10.1 South America Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Type (2021-2032)

10.2 South America Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Application (2021-2032)

10.3 South America Targeted Protein Degradation (TPD) Therapy Drugs Market Size by Country

10.3.1 South America Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Country (2021-2032)

10.3.2 South America Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value by Country (2021-2032)

10.3.3 Brazil Market Size and Forecast (2021-2032)

10.3.4 Argentina Market Size and Forecast (2021-2032)

## **11 MIDDLE EAST & AFRICA**

11.1 Middle East & Africa Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Type (2021-2032)

11.2 Middle East & Africa Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Application (2021-2032)

11.3 Middle East & Africa Targeted Protein Degradation (TPD) Therapy Drugs Market Size by Country

11.3.1 Middle East & Africa Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Country (2021-2032)

11.3.2 Middle East & Africa Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value by Country (2021-2032)

11.3.3 Turkey Market Size and Forecast (2021-2032)

11.3.4 Egypt Market Size and Forecast (2021-2032)

11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)

11.3.6 South Africa Market Size and Forecast (2021-2032)

## **12 MARKET DYNAMICS**

12.1 Targeted Protein Degradation (TPD) Therapy Drugs Market Drivers

12.2 Targeted Protein Degradation (TPD) Therapy Drugs Market Restraints

12.3 Targeted Protein Degradation (TPD) Therapy Drugs Trends Analysis

12.4 Porters Five Forces Analysis

12.4.1 Threat of New Entrants

12.4.2 Bargaining Power of Suppliers

12.4.3 Bargaining Power of Buyers

12.4.4 Threat of Substitutes

12.4.5 Competitive Rivalry

## **13 RAW MATERIAL AND INDUSTRY CHAIN**

13.1 Raw Material of Targeted Protein Degradation (TPD) Therapy Drugs and Key Manufacturers

13.2 Manufacturing Costs Percentage of Targeted Protein Degradation (TPD) Therapy Drugs

13.3 Targeted Protein Degradation (TPD) Therapy Drugs Production Process

13.4 Industry Value Chain Analysis

## **14 SHIPMENTS BY DISTRIBUTION CHANNEL**

14.1 Sales Channel

14.1.1 Direct to End-User

14.1.2 Distributors

14.2 Targeted Protein Degradation (TPD) Therapy Drugs Typical Distributors

14.3 Targeted Protein Degradation (TPD) Therapy Drugs Typical Customers

## **15 RESEARCH FINDINGS AND CONCLUSION**

## **16 APPENDIX**

16.1 Methodology

16.2 Research Process and Data Source

16.3 Disclaimer

## List Of Tables

### LIST OF TABLES

Table 1. Global Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value by Type, (USD Million), 2021 & 2025 & 2032

Table 2. Global Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value by Target Protein, (USD Million), 2021 & 2025 & 2032

Table 3. Global Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value by Administration Route, (USD Million), 2021 & 2025 & 2032

Table 4. Global Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value by Application, (USD Million), 2021 & 2025 & 2032

Table 5. BMS Basic Information, Manufacturing Base and Competitors

Table 6. BMS Major Business

Table 7. BMS Targeted Protein Degradation (TPD) Therapy Drugs Product and Services

Table 8. BMS Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 9. BMS Recent Developments/Updates

Table 10. Arvinas Basic Information, Manufacturing Base and Competitors

Table 11. Arvinas Major Business

Table 12. Arvinas Targeted Protein Degradation (TPD) Therapy Drugs Product and Services

Table 13. Arvinas Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 14. Arvinas Recent Developments/Updates

Table 15. Kymera Basic Information, Manufacturing Base and Competitors

Table 16. Kymera Major Business

Table 17. Kymera Targeted Protein Degradation (TPD) Therapy Drugs Product and Services

Table 18. Kymera Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 19. Kymera Recent Developments/Updates

Table 20. Nurix Basic Information, Manufacturing Base and Competitors

Table 21. Nurix Major Business

Table 22. Nurix Targeted Protein Degradation (TPD) Therapy Drugs Product and

## Services

Table 23. Nurix Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 24. Nurix Recent Developments/Updates

Table 25. C4 Therapeutics Basic Information, Manufacturing Base and Competitors

Table 26. C4 Therapeutics Major Business

Table 27. C4 Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Product and Services

Table 28. C4 Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 29. C4 Therapeutics Recent Developments/Updates

Table 30. Cullgen Basic Information, Manufacturing Base and Competitors

Table 31. Cullgen Major Business

Table 32. Cullgen Targeted Protein Degradation (TPD) Therapy Drugs Product and Services

Table 33. Cullgen Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 34. Cullgen Recent Developments/Updates

Table 35. Kintor Pharma Basic Information, Manufacturing Base and Competitors

Table 36. Kintor Pharma Major Business

Table 37. Kintor Pharma Targeted Protein Degradation (TPD) Therapy Drugs Product and Services

Table 38. Kintor Pharma Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 39. Kintor Pharma Recent Developments/Updates

Table 40. Prelude Therapeutics Basic Information, Manufacturing Base and Competitors

Table 41. Prelude Therapeutics Major Business

Table 42. Prelude Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Product and Services

Table 43. Prelude Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 44. Prelude Therapeutics Recent Developments/Updates

Table 45. AbbVie Basic Information, Manufacturing Base and Competitors

Table 46. AbbVie Major Business

Table 47. AbbVie Targeted Protein Degradation (TPD) Therapy Drugs Product and Services

Table 48. AbbVie Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 49. AbbVie Recent Developments/Updates

Table 50. Accutar Basic Information, Manufacturing Base and Competitors

Table 51. Accutar Major Business

Table 52. Accutar Targeted Protein Degradation (TPD) Therapy Drugs Product and Services

Table 53. Accutar Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 54. Accutar Recent Developments/Updates

Table 55. AnHorn Medicines Basic Information, Manufacturing Base and Competitors

Table 56. AnHorn Medicines Major Business

Table 57. AnHorn Medicines Targeted Protein Degradation (TPD) Therapy Drugs Product and Services

Table 58. AnHorn Medicines Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 59. AnHorn Medicines Recent Developments/Updates

Table 60. Astellas Basic Information, Manufacturing Base and Competitors

Table 61. Astellas Major Business

Table 62. Astellas Targeted Protein Degradation (TPD) Therapy Drugs Product and Services

Table 63. Astellas Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 64. Astellas Recent Developments/Updates

Table 65. Auron Therapeutics Basic Information, Manufacturing Base and Competitors

Table 66. Auron Therapeutics Major Business

Table 67. Auron Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Product and Services

Table 68. Auron Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 69. Auron Therapeutics Recent Developments/Updates

Table 70. Axter Therapeutics Basic Information, Manufacturing Base and Competitors

Table 71. Axter Therapeutics Major Business

Table 72. Axter Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Product and Services

Table 73. Axter Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 74. Axter Therapeutics Recent Developments/Updates

Table 75. Biotheryx Basic Information, Manufacturing Base and Competitors

Table 76. Biotheryx Major Business

Table 77. Biotheryx Targeted Protein Degradation (TPD) Therapy Drugs Product and Services

Table 78. Biotheryx Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 79. Biotheryx Recent Developments/Updates

Table 80. Dialectic Therapeutics Basic Information, Manufacturing Base and Competitors

Table 81. Dialectic Therapeutics Major Business

Table 82. Dialectic Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Product and Services

Table 83. Dialectic Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 84. Dialectic Therapeutics Recent Developments/Updates

Table 85. Hinoa Basic Information, Manufacturing Base and Competitors

Table 86. Hinoa Major Business

Table 87. Hinoa Targeted Protein Degradation (TPD) Therapy Drugs Product and Services

Table 88. Hinoa Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 89. Hinoa Recent Developments/Updates

Table 90. Hinoa Pharmaceuticals Basic Information, Manufacturing Base and Competitors

Table 91. Hinoa Pharmaceuticals Major Business

Table 92. Hinoa Pharmaceuticals Targeted Protein Degradation (TPD) Therapy Drugs Product and Services

Table 93. Hinoa Pharmaceuticals Targeted Protein Degradation (TPD) Therapy Drugs

Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 94. Hinova Pharmaceuticals Recent Developments/Updates

Table 95. Haisco Basic Information, Manufacturing Base and Competitors

Table 96. Haisco Major Business

Table 97. Haisco Targeted Protein Degradation (TPD) Therapy Drugs Product and Services

Table 98. Haisco Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 99. Haisco Recent Developments/Updates

Table 100. Leadingtac Basic Information, Manufacturing Base and Competitors

Table 101. Leadingtac Major Business

Table 102. Leadingtac Targeted Protein Degradation (TPD) Therapy Drugs Product and Services

Table 103. Leadingtac Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 104. Leadingtac Recent Developments/Updates

Table 105. Mitsubishi Tanabe Pharma America Basic Information, Manufacturing Base and Competitors

Table 106. Mitsubishi Tanabe Pharma America Major Business

Table 107. Mitsubishi Tanabe Pharma America Targeted Protein Degradation (TPD) Therapy Drugs Product and Services

Table 108. Mitsubishi Tanabe Pharma America Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 109. Mitsubishi Tanabe Pharma America Recent Developments/Updates

Table 110. NiKang Therapeutics Basic Information, Manufacturing Base and Competitors

Table 111. NiKang Therapeutics Major Business

Table 112. NiKang Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Product and Services

Table 113. NiKang Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 114. NiKang Therapeutics Recent Developments/Updates

Table 115. Ubix Therapeutics Basic Information, Manufacturing Base and Competitors

Table 116. Ubix Therapeutics Major Business

Table 117. Ubix Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Product and Services

Table 118. Ubix Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 119. Ubix Therapeutics Recent Developments/Updates

Table 120. Foghorn Therapeutics Basic Information, Manufacturing Base and Competitors

Table 121. Foghorn Therapeutics Major Business

Table 122. Foghorn Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Product and Services

Table 123. Foghorn Therapeutics Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 124. Foghorn Therapeutics Recent Developments/Updates

Table 125. Beigene, Ltd. Basic Information, Manufacturing Base and Competitors

Table 126. Beigene, Ltd. Major Business

Table 127. Beigene, Ltd. Targeted Protein Degradation (TPD) Therapy Drugs Product and Services

Table 128. Beigene, Ltd. Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 129. Beigene, Ltd. Recent Developments/Updates

Table 130. Jiangsu Hengrui Medicine Basic Information, Manufacturing Base and Competitors

Table 131. Jiangsu Hengrui Medicine Major Business

Table 132. Jiangsu Hengrui Medicine Targeted Protein Degradation (TPD) Therapy Drugs Product and Services

Table 133. Jiangsu Hengrui Medicine Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 134. Jiangsu Hengrui Medicine Recent Developments/Updates

Table 135. Qilu Pharmaceutical Basic Information, Manufacturing Base and Competitors

Table 136. Qilu Pharmaceutical Major Business

Table 137. Qilu Pharmaceutical Targeted Protein Degradation (TPD) Therapy Drugs Product and Services

Table 138. Qilu Pharmaceutical Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross

Margin and Market Share (2021-2026)

Table 139. Qilu Pharmaceutical Recent Developments/Updates

Table 140. Simcere Pharma Basic Information, Manufacturing Base and Competitors

Table 141. Simcere Pharma Major Business

Table 142. Simcere Pharma Targeted Protein Degradation (TPD) Therapy Drugs Product and Services

Table 143. Simcere Pharma Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 144. Simcere Pharma Recent Developments/Updates

Table 145. Chia Tai Tianqing Pharmaceutical Basic Information, Manufacturing Base and Competitors

Table 146. Chia Tai Tianqing Pharmaceutical Major Business

Table 147. Chia Tai Tianqing Pharmaceutical Targeted Protein Degradation (TPD) Therapy Drugs Product and Services

Table 148. Chia Tai Tianqing Pharmaceutical Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 149. Chia Tai Tianqing Pharmaceutical Recent Developments/Updates

Table 150. Global Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Manufacturer (2021-2026) & (K Units)

Table 151. Global Targeted Protein Degradation (TPD) Therapy Drugs Revenue by Manufacturer (2021-2026) & (USD Million)

Table 152. Global Targeted Protein Degradation (TPD) Therapy Drugs Average Price by Manufacturer (2021-2026) & (US\$/Unit)

Table 153. Market Position of Manufacturers in Targeted Protein Degradation (TPD) Therapy Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025

Table 154. Head Office and Targeted Protein Degradation (TPD) Therapy Drugs Production Site of Key Manufacturer

Table 155. Targeted Protein Degradation (TPD) Therapy Drugs Market: Company Product Type Footprint

Table 156. Targeted Protein Degradation (TPD) Therapy Drugs Market: Company Product Application Footprint

Table 157. Targeted Protein Degradation (TPD) Therapy Drugs New Market Entrants and Barriers to Market Entry

Table 158. Targeted Protein Degradation (TPD) Therapy Drugs Mergers, Acquisition, Agreements, and Collaborations

Table 159. Global Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value by Region (2021-2025-2032) & (USD Million) & CAGR

Table 160. Global Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Region (2021-2026) & (K Units)

Table 161. Global Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Region (2027-2032) & (K Units)

Table 162. Global Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value by Region (2021-2026) & (USD Million)

Table 163. Global Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value by Region (2027-2032) & (USD Million)

Table 164. Global Targeted Protein Degradation (TPD) Therapy Drugs Average Price by Region (2021-2026) & (US\$/Unit)

Table 165. Global Targeted Protein Degradation (TPD) Therapy Drugs Average Price by Region (2027-2032) & (US\$/Unit)

Table 166. Global Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Type (2021-2026) & (K Units)

Table 167. Global Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Type (2027-2032) & (K Units)

Table 168. Global Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value by Type (2021-2026) & (USD Million)

Table 169. Global Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value by Type (2027-2032) & (USD Million)

Table 170. Global Targeted Protein Degradation (TPD) Therapy Drugs Average Price by Type (2021-2026) & (US\$/Unit)

Table 171. Global Targeted Protein Degradation (TPD) Therapy Drugs Average Price by Type (2027-2032) & (US\$/Unit)

Table 172. Global Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Application (2021-2026) & (K Units)

Table 173. Global Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Application (2027-2032) & (K Units)

Table 174. Global Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value by Application (2021-2026) & (USD Million)

Table 175. Global Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value by Application (2027-2032) & (USD Million)

Table 176. Global Targeted Protein Degradation (TPD) Therapy Drugs Average Price by Application (2021-2026) & (US\$/Unit)

Table 177. Global Targeted Protein Degradation (TPD) Therapy Drugs Average Price by Application (2027-2032) & (US\$/Unit)

Table 178. North America Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Type (2021-2026) & (K Units)

Table 179. North America Targeted Protein Degradation (TPD) Therapy Drugs Sales

Quantity by Type (2027-2032) & (K Units)

Table 180. North America Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Application (2021-2026) & (K Units)

Table 181. North America Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Application (2027-2032) & (K Units)

Table 182. North America Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Country (2021-2026) & (K Units)

Table 183. North America Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Country (2027-2032) & (K Units)

Table 184. North America Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value by Country (2021-2026) & (USD Million)

Table 185. North America Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value by Country (2027-2032) & (USD Million)

Table 186. Europe Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Type (2021-2026) & (K Units)

Table 187. Europe Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Type (2027-2032) & (K Units)

Table 188. Europe Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Application (2021-2026) & (K Units)

Table 189. Europe Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Application (2027-2032) & (K Units)

Table 190. Europe Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Country (2021-2026) & (K Units)

Table 191. Europe Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Country (2027-2032) & (K Units)

Table 192. Europe Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value by Country (2021-2026) & (USD Million)

Table 193. Europe Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value by Country (2027-2032) & (USD Million)

Table 194. Asia-Pacific Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Type (2021-2026) & (K Units)

Table 195. Asia-Pacific Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Type (2027-2032) & (K Units)

Table 196. Asia-Pacific Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Application (2021-2026) & (K Units)

Table 197. Asia-Pacific Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Application (2027-2032) & (K Units)

Table 198. Asia-Pacific Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Region (2021-2026) & (K Units)

Table 199. Asia-Pacific Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Region (2027-2032) & (K Units)

Table 200. Asia-Pacific Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value by Region (2021-2026) & (USD Million)

Table 201. Asia-Pacific Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value by Region (2027-2032) & (USD Million)

Table 202. South America Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Type (2021-2026) & (K Units)

Table 203. South America Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Type (2027-2032) & (K Units)

Table 204. South America Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Application (2021-2026) & (K Units)

Table 205. South America Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Application (2027-2032) & (K Units)

Table 206. South America Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Country (2021-2026) & (K Units)

Table 207. South America Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Country (2027-2032) & (K Units)

Table 208. South America Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value by Country (2021-2026) & (USD Million)

Table 209. South America Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value by Country (2027-2032) & (USD Million)

Table 210. Middle East & Africa Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Type (2021-2026) & (K Units)

Table 211. Middle East & Africa Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Type (2027-2032) & (K Units)

Table 212. Middle East & Africa Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Application (2021-2026) & (K Units)

Table 213. Middle East & Africa Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Application (2027-2032) & (K Units)

Table 214. Middle East & Africa Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Country (2021-2026) & (K Units)

Table 215. Middle East & Africa Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity by Country (2027-2032) & (K Units)

Table 216. Middle East & Africa Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value by Country (2021-2026) & (USD Million)

Table 217. Middle East & Africa Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value by Country (2027-2032) & (USD Million)

Table 218. Targeted Protein Degradation (TPD) Therapy Drugs Raw Material

Table 219. Key Manufacturers of Targeted Protein Degradation (TPD) Therapy Drugs Raw Materials

Table 220. Targeted Protein Degradation (TPD) Therapy Drugs Typical Distributors

Table 221. Targeted Protein Degradation (TPD) Therapy Drugs Typical Customers

## List Of Figures

### LIST OF FIGURES

- Figure 1. Targeted Protein Degradation (TPD) Therapy Drugs Picture
- Figure 2. Global Targeted Protein Degradation (TPD) Therapy Drugs Revenue by Type, (USD Million), 2021 & 2025 & 2032
- Figure 3. Global Targeted Protein Degradation (TPD) Therapy Drugs Revenue Market Share by Type in 2025
- Figure 4. PROTAC Examples
- Figure 5. Molecular Glues Examples
- Figure 6. Others Examples
- Figure 7. Global Targeted Protein Degradation (TPD) Therapy Drugs Revenue by Target Protein, (USD Million), 2021 & 2025 & 2032
- Figure 8. Global Targeted Protein Degradation (TPD) Therapy Drugs Revenue Market Share by Target Protein in 2025
- Figure 9. Degradation of Transcription Factors Type Examples
- Figure 10. Degradation of Scaffold Proteins Type Examples
- Figure 11. Others Examples
- Figure 12. Global Targeted Protein Degradation (TPD) Therapy Drugs Revenue by Administration Route, (USD Million), 2021 & 2025 & 2032
- Figure 13. Global Targeted Protein Degradation (TPD) Therapy Drugs Revenue Market Share by Administration Route in 2025
- Figure 14. Oral Drugs Examples
- Figure 15. Injectable Drugs Examples
- Figure 16. Others Examples
- Figure 17. Global Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
- Figure 18. Global Targeted Protein Degradation (TPD) Therapy Drugs Revenue Market Share by Application in 2025
- Figure 19. Cancer Examples
- Figure 20. Immune Diseases Examples
- Figure 21. Others Examples
- Figure 22. Global Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value, (USD Million): 2021 & 2025 & 2032
- Figure 23. Global Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value and Forecast (2021-2032) & (USD Million)
- Figure 24. Global Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity (2021-2032) & (K Units)

- Figure 25. Global Targeted Protein Degradation (TPD) Therapy Drugs Price (2021-2032) & (US\$/Unit)
- Figure 26. Global Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity Market Share by Manufacturer in 2025
- Figure 27. Global Targeted Protein Degradation (TPD) Therapy Drugs Revenue Market Share by Manufacturer in 2025
- Figure 28. Producer Shipments of Targeted Protein Degradation (TPD) Therapy Drugs by Manufacturer Sales (\$MM) and Market Share (%): 2025
- Figure 29. Top 3 Targeted Protein Degradation (TPD) Therapy Drugs Manufacturer (Revenue) Market Share in 2025
- Figure 30. Top 6 Targeted Protein Degradation (TPD) Therapy Drugs Manufacturer (Revenue) Market Share in 2025
- Figure 31. Global Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity Market Share by Region (2021-2032)
- Figure 32. Global Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value Market Share by Region (2021-2032)
- Figure 33. North America Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value (2021-2032) & (USD Million)
- Figure 34. Europe Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value (2021-2032) & (USD Million)
- Figure 35. Asia-Pacific Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value (2021-2032) & (USD Million)
- Figure 36. South America Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value (2021-2032) & (USD Million)
- Figure 37. Middle East & Africa Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value (2021-2032) & (USD Million)
- Figure 38. Global Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity Market Share by Type (2021-2032)
- Figure 39. Global Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value Market Share by Type (2021-2032)
- Figure 40. Global Targeted Protein Degradation (TPD) Therapy Drugs Average Price by Type (2021-2032) & (US\$/Unit)
- Figure 41. Global Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity Market Share by Application (2021-2032)
- Figure 42. Global Targeted Protein Degradation (TPD) Therapy Drugs Revenue Market Share by Application (2021-2032)
- Figure 43. Global Targeted Protein Degradation (TPD) Therapy Drugs Average Price by Application (2021-2032) & (US\$/Unit)
- Figure 44. North America Targeted Protein Degradation (TPD) Therapy Drugs Sales

Quantity Market Share by Type (2021-2032)

Figure 45. North America Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity Market Share by Application (2021-2032)

Figure 46. North America Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity Market Share by Country (2021-2032)

Figure 47. North America Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value Market Share by Country (2021-2032)

Figure 48. United States Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value (2021-2032) & (USD Million)

Figure 49. Canada Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value (2021-2032) & (USD Million)

Figure 50. Mexico Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value (2021-2032) & (USD Million)

Figure 51. Europe Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity Market Share by Type (2021-2032)

Figure 52. Europe Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity Market Share by Application (2021-2032)

Figure 53. Europe Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity Market Share by Country (2021-2032)

Figure 54. Europe Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value Market Share by Country (2021-2032)

Figure 55. Germany Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value (2021-2032) & (USD Million)

Figure 56. France Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value (2021-2032) & (USD Million)

Figure 57. United Kingdom Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value (2021-2032) & (USD Million)

Figure 58. Russia Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value (2021-2032) & (USD Million)

Figure 59. Italy Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value (2021-2032) & (USD Million)

Figure 60. Asia-Pacific Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity Market Share by Type (2021-2032)

Figure 61. Asia-Pacific Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity Market Share by Application (2021-2032)

Figure 62. Asia-Pacific Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity Market Share by Region (2021-2032)

Figure 63. Asia-Pacific Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value Market Share by Region (2021-2032)

Figure 64. China Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value (2021-2032) & (USD Million)

Figure 65. Japan Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value (2021-2032) & (USD Million)

Figure 66. South Korea Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value (2021-2032) & (USD Million)

Figure 67. India Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value (2021-2032) & (USD Million)

Figure 68. Southeast Asia Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value (2021-2032) & (USD Million)

Figure 69. Australia Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value (2021-2032) & (USD Million)

Figure 70. South America Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity Market Share by Type (2021-2032)

Figure 71. South America Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity Market Share by Application (2021-2032)

Figure 72. South America Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity Market Share by Country (2021-2032)

Figure 73. South America Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value Market Share by Country (2021-2032)

Figure 74. Brazil Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value (2021-2032) & (USD Million)

Figure 75. Argentina Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value (2021-2032) & (USD Million)

Figure 76. Middle East & Africa Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity Market Share by Type (2021-2032)

Figure 77. Middle East & Africa Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity Market Share by Application (2021-2032)

Figure 78. Middle East & Africa Targeted Protein Degradation (TPD) Therapy Drugs Sales Quantity Market Share by Country (2021-2032)

Figure 79. Middle East & Africa Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value Market Share by Country (2021-2032)

Figure 80. Turkey Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value (2021-2032) & (USD Million)

Figure 81. Egypt Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value (2021-2032) & (USD Million)

Figure 82. Saudi Arabia Targeted Protein Degradation (TPD) Therapy Drugs Consumption Value (2021-2032) & (USD Million)

Figure 83. South Africa Targeted Protein Degradation (TPD) Therapy Drugs

Consumption Value (2021-2032) & (USD Million)

Figure 84. Targeted Protein Degradation (TPD) Therapy Drugs Market Drivers

Figure 85. Targeted Protein Degradation (TPD) Therapy Drugs Market Restraints

Figure 86. Targeted Protein Degradation (TPD) Therapy Drugs Market Trends

Figure 87. Porters Five Forces Analysis

Figure 88. Manufacturing Cost Structure Analysis of Targeted Protein Degradation (TPD) Therapy Drugs in 2025

Figure 89. Manufacturing Process Analysis of Targeted Protein Degradation (TPD) Therapy Drugs

Figure 90. Targeted Protein Degradation (TPD) Therapy Drugs Industrial Chain

Figure 91. Sales Channel: Direct to End-User vs Distributors

Figure 92. Direct Channel Pros & Cons

Figure 93. Indirect Channel Pros & Cons

Figure 94. Methodology

Figure 95. Research Process and Data Source

## I would like to order

Product name: Global Targeted Protein Degradation (TPD) Therapy Drugs Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Product link: <https://marketpublishers.com/r/T0F3BCF73F0EEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T0F3BCF73F0EEN.html>